Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiopharmaceutical therapeutics for oncology. Its pipeline includes ATNM-400 (non-PSMA solid tumor candidate), Actimab-A (CD33-targeted for AML/MDS and MDSC-targeting in solid tumors), Iomab-B (CD45-targeted bone marrow transplant conditioning), and Iomab-ACT (conditioning for cell and gene therapies). The company has treated over 500 patients across 15+ clinical trials and maintains an end-to-end radiopharmaceutical supply chain.
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001213900-26-036504 | EDGAR | 76K words |
| 2025-03-31 | 2024-12-31 | 0001213900-25-026371 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0001213900-24-028038 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001213900-23-025597 | EDGAR | — |
| 2022-03-25 | 2021-12-31 | 0001213900-22-015208 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001213900-21-019297 | EDGAR | — |
| 2020-05-08 | 2019-12-31 | 0001213900-20-011475 | EDGAR | — |
| 2019-03-15 | 2018-12-31 | 0001213900-19-004269 | EDGAR | — |
| 2018-03-16 | 2017-12-31 | 0001213900-18-003091 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001213900-17-002461 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001213900-25-110979 | EDGAR | 55K words |
| 2025-08-08 | 2025-06-30 | 0001213900-25-073743 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001213900-25-041614 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001213900-24-098534 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0001213900-24-065239 | EDGAR | — |
| 2024-04-26 | 2024-03-31 | 0001213900-24-036699 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001213900-23-082459 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001213900-23-067199 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001213900-23-039902 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001213900-22-072371 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001213900-22-047496 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001213900-22-026538 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-13 | 0001213900-26-016559 | EDGAR | 1K words |
| 2025-11-26 | 0001213900-25-115586 | EDGAR | — |
| 2025-05-09 | 0001213900-25-041582 | EDGAR | — |
| 2024-11-27 | 0001213900-24-103498 | EDGAR | — |
| 2024-11-05 | 0001213900-24-094622 | EDGAR | — |
| 2024-08-05 | 0001213900-24-064993 | EDGAR | — |
| 2023-12-01 | 0001213900-23-092089 | EDGAR | — |
| 2023-03-10 | 0001213900-23-019289 | EDGAR | — |
| 2023-02-21 | 0001213900-23-013059 | EDGAR | — |
| 2022-12-30 | 0001213900-22-084094 | EDGAR | — |
232 total filings indexed. 200 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001388320 |
| Ticker | ATNM |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.actiniumpharma.com |
| Listed | 2007-07-19 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report